[go: up one dir, main page]

DE69824234D1 - Menschliche-"CDR-grafted"-Antikörper gegen Gangliosid gm2 - Google Patents

Menschliche-"CDR-grafted"-Antikörper gegen Gangliosid gm2

Info

Publication number
DE69824234D1
DE69824234D1 DE69824234T DE69824234T DE69824234D1 DE 69824234 D1 DE69824234 D1 DE 69824234D1 DE 69824234 T DE69824234 T DE 69824234T DE 69824234 T DE69824234 T DE 69824234T DE 69824234 D1 DE69824234 D1 DE 69824234D1
Authority
DE
Germany
Prior art keywords
cdr
seq
chain
human
ganglioside
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69824234T
Other languages
English (en)
Other versions
DE69824234T2 (de
Inventor
Nakamura Kazuyasu
Hanai Nobuo
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Kyowa Kirin Co Ltd
Original Assignee
Kyowa Hakko Kogyo Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kyowa Hakko Kogyo Co Ltd filed Critical Kyowa Hakko Kogyo Co Ltd
Publication of DE69824234D1 publication Critical patent/DE69824234D1/de
Application granted granted Critical
Publication of DE69824234T2 publication Critical patent/DE69824234T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/92Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving lipids, e.g. cholesterol, lipoproteins, or their receptors
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/20Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/70Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732Antibody-dependent cellular cytotoxicity [ADCC]
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/70Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/734Complement-dependent cytotoxicity [CDC]
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Biophysics (AREA)
  • Urology & Nephrology (AREA)
  • Cell Biology (AREA)
  • Biomedical Technology (AREA)
  • Analytical Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Endocrinology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physics & Mathematics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Saccharide Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
DE69824234T 1997-03-19 1998-03-19 Menschliche"CDR-grafted"-Antikörper gegen Gangliosid GM2 Expired - Lifetime DE69824234T2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP06698197A JP4550947B2 (ja) 1997-03-19 1997-03-19 ガングリオシドgm2に対するヒト型相補性決定領域(cdr)移植抗体
JP6698197 1997-03-19

Publications (2)

Publication Number Publication Date
DE69824234D1 true DE69824234D1 (de) 2004-07-08
DE69824234T2 DE69824234T2 (de) 2005-06-23

Family

ID=13331716

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69824234T Expired - Lifetime DE69824234T2 (de) 1997-03-19 1998-03-19 Menschliche"CDR-grafted"-Antikörper gegen Gangliosid GM2

Country Status (7)

Country Link
EP (1) EP0882794B1 (de)
JP (1) JP4550947B2 (de)
AT (1) ATE268382T1 (de)
AU (1) AU751948B2 (de)
CA (1) CA2226400C (de)
DE (1) DE69824234T2 (de)
ES (1) ES2219802T3 (de)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6407734B1 (en) 1994-10-31 2002-06-18 Nec-Mitsubishi Electric Visual Systems Corporation Power supply system capable of reducing power consumption during interruption of an external input signal given to an operating circuit
US7241568B2 (en) 1996-04-03 2007-07-10 Kyowa Hakko Kogyo Co., Ltd. Anti-fibroblast growth factor-8 monoclonal antibody
DK1176195T3 (da) 1999-04-09 2013-06-24 Kyowa Hakko Kirin Co Ltd Fremgangsmåde til at kontrollere aktiviteten af immunologisk funktionelt molekyle
US6693176B1 (en) 1999-07-23 2004-02-17 University Of Massachusetts Antitumor antibodies, proteins, and uses thereof
AU7449200A (en) * 1999-09-30 2001-04-30 Kyowa Hakko Kogyo Co. Ltd. Derivatives of antibody against ganglioside gm2
AU2016204535C1 (en) * 2000-04-12 2017-02-23 Laboratoire Français Du Fractionnement Et Des Biotechnologies Anti-D monoclonal antibodies
FR2807767B1 (fr) * 2000-04-12 2005-01-14 Lab Francais Du Fractionnement Anticorps monoclonaux anti-d
JP2001299349A (ja) * 2000-04-19 2001-10-30 Suntory Ltd 新規組換え型抗体とそのcdrのアミノ酸配列およびそれをコードする遺伝子
US6946292B2 (en) 2000-10-06 2005-09-20 Kyowa Hakko Kogyo Co., Ltd. Cells producing antibody compositions with increased antibody dependent cytotoxic activity
EA013224B1 (ru) * 2000-10-06 2010-04-30 Киова Хакко Кирин Ко., Лтд. Клетки, продуцирующие композиции антител
AU2002346127B2 (en) * 2001-06-28 2008-05-29 Kyowa Hakko Kirin Co., Ltd. Humanized antibody against fibroblast growth factor-8 and fragment of the antibody
WO2003049704A2 (en) 2001-12-11 2003-06-19 University Of Massachusetts Antibodies to treat cancer
ATE429249T1 (de) * 2001-12-28 2009-05-15 Kyowa Hakko Kogyo Kk Anti-fgf-8 antikörper gegen arthritis
AU2003236017B2 (en) 2002-04-09 2009-03-26 Kyowa Kirin Co., Ltd. Drug containing antibody composition
US20040115204A1 (en) 2002-12-11 2004-06-17 Fanger Gary R. Antibodies to treat cancer
AU2004279736A1 (en) * 2003-10-09 2005-04-21 Kyowa Hakko Kirin Co., Ltd. Antibody composition specifically binding to ganglioside GM2
US7691810B2 (en) 2003-10-09 2010-04-06 Kyowa Hakko Kirin Co., Ltd Method of producing recombinant antithrombin III composition
EP2107115A1 (de) 2007-01-24 2009-10-07 Kyowa Hakko Kirin Co., Ltd. Genetisch rekombinante antikörperzusammensetzung zur anbindung insbesondere an gangliosid gm2
FR2953841B1 (fr) * 2009-12-16 2011-12-30 Centre Nat Rech Scient Anticorps diriges contre le recepteur de la transferrine et leurs utilisations pour l'immunotherapie des tumeurs qui dependent du fer
EP2543727B1 (de) 2010-03-02 2016-08-31 Kyowa Hakko Kirin Co., Ltd. Modifizierte antikörperzusammensetzung
JP6310397B2 (ja) * 2012-12-06 2018-04-11 国立大学法人金沢大学 中皮腫の治療方法

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU669379B2 (en) * 1992-09-07 1996-06-06 Kyowa Hakko Kirin Co., Ltd. Humanized antibodies

Also Published As

Publication number Publication date
EP0882794B1 (de) 2004-06-02
JPH10257893A (ja) 1998-09-29
ATE268382T1 (de) 2004-06-15
AU5942098A (en) 1998-10-01
EP0882794A3 (de) 1999-06-16
JP4550947B2 (ja) 2010-09-22
CA2226400C (en) 2008-12-02
CA2226400A1 (en) 1998-09-19
AU751948B2 (en) 2002-09-05
EP0882794A2 (de) 1998-12-09
ES2219802T3 (es) 2004-12-01
DE69824234T2 (de) 2005-06-23

Similar Documents

Publication Publication Date Title
DE69824234D1 (de) Menschliche-"CDR-grafted"-Antikörper gegen Gangliosid gm2
FR12C0004I2 (fr) Anticorps contre l'antigene ctla-4 humain et utilisation
WO1998050433A3 (en) Human monoclonal antibodies to epidermal growth factor receptor
TR200101831T2 (tr) CTLA-4 için insan monoklonal antikorları.
CA2290485A1 (en) Method for the production of non-immunogenic proteins
ATE373712T1 (de) Natürlicher menschlicher antikörper
WO1998018826A3 (en) Anti-CCR5 antibodies and methods of use therefor
NZ503763A (en) Antigenic compositions and vaccines comprising a high molecular weight (HMW) protein of Clamydia for therapeutic and prophylactic use
CA2267072A1 (en) Reconstituted human anti-hm1.24 antibody
DK1157042T3 (da) Fremstilling af tetravalente antistoffer
FI973354A0 (fi) MAG-geenejä
EE05497B1 (et) Polüpeptiid, lahustuv CRAM-1 polüpeptiid, polünukleotiid ja antikeha
EP1530579A4 (de) Rekombinante antikörper sowie zusammensetzungen und verfahren zu deren herstellung und verwendung
NO943653L (no) Rekombinante, humane HIV-nöytraliserende monoklonale antistoffer for forebyggelse og behandling av HIV-infeksjon
DE69922834D1 (de) Humanisierter antikörper spezifisch für das oberflächenantigen pre-s1 von hbv und dessen präparation
GR3034035T3 (en) A process for the preparation of factor ix from biological sources
AU3582593A (en) Antigen recognized by patients with antibody associated lambert-eaton myasthenic syndrome (LEMS), DNA encoding same and uses thereof
EP1191096A4 (de) Neues protein und dessen dns
DE59207362D1 (de) Monoklonale Antikörper gegen den Plasmin-Antiplasmin Komplex, Verfahren zu ihrer Herstellung sowie ihre Verwendung
BR9911388A (pt) Imunógeno de somatostatina sintético para promoção de crescimento em animais de fazenda
SE9600436D0 (sv) Vaccine against hantavirus
WO2020232243A3 (en) Antibodies to sudan and ebola virus
IT1291419B1 (it) Gruppo illuminante per l'illuminazione di acquari,terrari e simili.
DE69128095D1 (de) Azelluläre impfstoffe
AU2293300A (en) Ewing's tumour antigen, nucleic acid and antibodies

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8327 Change in the person/name/address of the patent owner

Owner name: KYOWA HAKKO KIRIN CO., LTD., TOKYO, JP